TY - JOUR
T1 - Recurrent Clostridium difficile infection is associated with increased mortality
AU - Olsen, M. A.
AU - Yan, Y.
AU - Reske, K. A.
AU - Zilberberg, M. D.
AU - Dubberke, E. R.
N1 - Funding Information:
The authors report a grant from Cubist Pharmaceuticals for the conduct of this study. E.R.D. has been a consultant for Sanofi Pasteur, Merck and Pfizer, and reports grants from or participation in clinical trials with Sanofi-Pasteur, Merck, Cubist Pharmaceuticals and Viropharma unrelated to this study. M.A.O. has been a consultant for Pfizer, Sanofi Pasteur, and Merck, and reports a grant from Sanofi Pasteur unrelated to this study. M.Z. has been a consultant for Pfizer, Astellas and CareFusion, and reports grants or research support from Viropharma, Tetraphase and Theravance unrelated to this study. Y.Y. and K.A.R. report no conflicts of interest.
Funding Information:
This work was supported by Cubist Pharmaceuticals, Lexington, MA, USA.
Publisher Copyright:
© 2014 European Society of Clinical Microbiology and Infectious Diseases.
PY - 2015/2/1
Y1 - 2015/2/1
N2 - Clostridium difficile infections (CDI) are associated with decreased survival, and up to 30% of CDI patients may experience a recurrence. Data on the impact of recurrent CDI on mortality are scarce. The purpose of this study was to determine whether recurrent CDI was independently associated with decreased 6-month survival compared with patients with CDI who did not develop a recurrence. We performed a retrospective cohort study at an academic, urban, tertiary care hospital. Data were collected from the electronic medical record and chart review. CDI patients were followed for 180 days from the end of their index hospital discharge or end of index CDI antibiotic treatment, whichever was later, to determine mortality. Kaplan-Meier analysis was used to compare patient mortality by recurrent CDI status. Cox proportional hazards models were used to determine independent risk factors for death within 180 days. In all, 3958 patients aged ≥ 18 years who developed an initial CDI episode from 2003 to 2009, including 421 patients with recurrent CDI, were included in the study. Thirty-six per cent of persons with recurrent CDI died within 180 days, compared with 26% of persons without CDI recurrence (log-rank p <0.001). Recurrent CDI was associated with significantly higher hazards of death within 180 days, adjusting for demographics, comorbidities and medications received during the index CDI hospitalization (hazard ratio 1.33; 95% CI 1.12-1.58). Recurrent CDI is associated with significantly increased risk of death within 6 months after completion of their initial CDI treatment compared with CDI patients who do not develop a recurrence.
AB - Clostridium difficile infections (CDI) are associated with decreased survival, and up to 30% of CDI patients may experience a recurrence. Data on the impact of recurrent CDI on mortality are scarce. The purpose of this study was to determine whether recurrent CDI was independently associated with decreased 6-month survival compared with patients with CDI who did not develop a recurrence. We performed a retrospective cohort study at an academic, urban, tertiary care hospital. Data were collected from the electronic medical record and chart review. CDI patients were followed for 180 days from the end of their index hospital discharge or end of index CDI antibiotic treatment, whichever was later, to determine mortality. Kaplan-Meier analysis was used to compare patient mortality by recurrent CDI status. Cox proportional hazards models were used to determine independent risk factors for death within 180 days. In all, 3958 patients aged ≥ 18 years who developed an initial CDI episode from 2003 to 2009, including 421 patients with recurrent CDI, were included in the study. Thirty-six per cent of persons with recurrent CDI died within 180 days, compared with 26% of persons without CDI recurrence (log-rank p <0.001). Recurrent CDI was associated with significantly higher hazards of death within 180 days, adjusting for demographics, comorbidities and medications received during the index CDI hospitalization (hazard ratio 1.33; 95% CI 1.12-1.58). Recurrent CDI is associated with significantly increased risk of death within 6 months after completion of their initial CDI treatment compared with CDI patients who do not develop a recurrence.
KW - Clostridium difficile
KW - Cohort
KW - Epidemiology
KW - Mortality
KW - Recurrence
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=84923034822&partnerID=8YFLogxK
U2 - 10.1016/j.cmi.2014.08.017
DO - 10.1016/j.cmi.2014.08.017
M3 - Article
C2 - 25658560
AN - SCOPUS:84923034822
SN - 1198-743X
VL - 21
SP - 164
EP - 170
JO - Clinical Microbiology and Infection
JF - Clinical Microbiology and Infection
IS - 2
ER -